SCYX News and Press, SCYNEXIS Inc. From 12/22/21

JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 3.37 million shares ...

JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that BREXAFEMME ® (ibrexafungerp tablets...

Scynexis (NASDAQ:SCYX) announces that the EMA has granted orphan medicinal product designation to ibrexafungerp for the indication of invasive candidiasis (IC). Shares up 2.3% premarket at $6.78. Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclus...

Orphan medicinal product designation will provide at least 10 years of market exclusivity in the EU for ibrexafungerp for invasive candidiasis. SCYNEXIS recently was awarded a new patent in the U.S. and obtained allowance of an additional European patent application, expanding lif...

Scynexis (NASDAQ:SCYX) announces initiation of a Phase 3 study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a step-down therapy for patients with invasive candidiasis (IC) and/or candidemia compared to oral fluconazole. Shares up 1.9% premarket at $6.50...

SCYNEXIS is initiating a global Phase 3 study to evaluate oral ibrexafungerp as a step-down treatment for invasive candidiasis (IC), including candidemia. Study provides an expeditious path toward approval of ibrexafungerp as the first non-azole oral therapy for invasive candidias...

SCYNEXIS (NASDAQ:SCYX) has announced grants of stock options to two new employees to purchase an aggregate of 5,200 shares of SCYNEXIS common stock at a per share exercise price of $7.38, the closing trading price on Nov. 30. The stock options were granted as material inducements to the new e...

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 1.2 million shares o...

JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that BREXAFEMME ® (ibrexafungerp tablets) has b...

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its nov...